Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 15/20 | 0.53 |
| ▸ | APP | P05067 | 2/20 | 0.44 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.43 |
| ▸ | TTK | P33981 | 2/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3305065 | 0.88 | NR1H2 (0.53) | NR1H2TTKNR1H3 | |
| SCHEMBL21462497 | 0.77 | NR1H2 (0.48) | NR1H2ATRATRIPNR1H3 | |
| SCHEMBL23327852 | 0.76 | NR1H2 (0.48) | NR1H2ATRATRIPNR1H3 | |
| SCHEMBL3307205 | 0.76 | NR1H2 (0.49) | NR1H2APPATRATRIP | |
| SCHEMBL4356842 | 0.75 | NR1H2 (0.52) | NR1H2NR1H3 | |
| SCHEMBL4728003 | 0.75 | NR1H2 (0.54) | NR1H2NR1H3 | |
| SCHEMBL17220650 | 0.74 | NR1H2 (0.75) | NR1H2NR1H3 | |
| SCHEMBL21841775 | 0.73 | NR1H2 (0.44) | NR1H2NR1H3 | |
| SCHEMBL29631943 | 0.73 | L3MBTL1 (0.60) | NR1H2ATRATRIP | |
| SCHEMBL19013605 | 0.73 | L3MBTL1 (0.60) | NR1H2ATRATRIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121655-A1 | NOVEL 2-HETEROARYL SUBSTITUTED INDOLES 695 | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | claimed |
| WO-2008108729-A1 | NOVEL 2-HETEROARYL SUBSTITUTED INDOLES 695 | ASTRAZENECA AB (SE) | 2008-09-12 | — | — | WO | claimed |
| US-20100098631-A1 | Novel-2-Heteroaryl Substituted Indoles 695 | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| US-20100098631-A1 | Novel-2-Heteroaryl Substituted Indoles 695 | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| US-20100098631-A1 | Novel-2-Heteroaryl Substituted Indoles 695 | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| EP-2121655-A1 | NOVEL 2-HETEROARYL SUBSTITUTED INDOLES 695 | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008108729-A1 | NOVEL 2-HETEROARYL SUBSTITUTED INDOLES 695 | ASTRAZENECA AB (SE) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008108729-A1 | NOVEL 2-HETEROARYL SUBSTITUTED INDOLES 695 | ASTRAZENECA AB (SE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100098631-A1 | Novel-2-Heteroaryl Substituted Indoles 695 | APP, IDO2, IDO1 | NR1H2 1715/4885APP 1/4885ATR 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.